The Cannabinoid Healing Chart, Sativex and Cannabis Science

tikidood over at GreenPassion.org shared an interesting chart, Titled: What Ails You, on the message boards. I really must recommend the community forum at GreenPassion.org; they’re a helpful bunch and really open about sharing wisdom.

This could really help a patient when choosing a strain that’s been lab-tested, or for someone like me, who makes medicine for myself and my dad. I will continue to research this, any insights the community at large wants to share are welcome here.

CBD aka Cannabidiol

“Cannabidiol (CBD) is a cannabinoid found in Cannabis. It is a major constituent of the plant, representing up to 40% in its extracts.[2]

It has displayed sedative effects in animal tests.[3] Some research, however, indicates that CBD can increase alertness.[4] It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver.

Medically, it has been shown to relieve convulsioninflammationanxiety, and nausea, as well as inhibit cancer cell growth.[5] Recent studies have shown cannabidiol to be as effective as atypical antipsychotics in treating schizophrenia.[6] Studies have also shown that it may relieve symptoms of dystonia.[7][8]

In November 2007, it was reported that CBD reduces growth of aggressive human breast cancer cells in vitro and reduces their invasiveness.

A 2008 study published in the British Journal of Psychiatry showed significant differences in Oxford-Liverpool Inventory of Feelings and Experiences scores between three groups: The first consisted of non-cannabis users, the second consisted of users with Δ9-THC detected, and the third consisted of users with both Δ9-THC and CBD detected. The Δ9-THC only group scored significantly higher for unusual experiences than the Δ9-THC and CBD group, whereas the Δ9-THC and CBD group had significantly lower introvertive anhedonia scores than the Δ9-THC only group and non-cannabis user group. This research indicates that CBD acts as an anti-psychotic and may counteract the potential effects of THC on individuals with latent schizophrenia.[9] “

Source: http://en.wikipedia.org/wiki/Cannabidiol

CBG aka Cannabigerol

Cannabigerol (CBG) is a non-psychoactive cannabinoid found in the Cannabis genus of plants. Cannabigerol is found in higher concentrations in hemp rather than in varieties of Cannabis with high THC content (the kind used as a drug).

Cannabigerol has been found to act as a high affinity α2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist.[1] It also binds to the CB2 receptor, but whether it acts as an agonist or antagonist at this site is unknown.[1]

Cannabigerol has been shown to relieve intraoccular pressure, which may be of benefit in the treatment of glaucoma.[2][3]

Source: http://en.wikipedia.org/wiki/Cannabigerol

CBN aka Cannabinol

Cannabinol (CBN) is the primary product of THC degradation, and there is usually little of it in a fresh plant. CBN content increases as THC degrades in storage, and with exposure to light and air. It is only mildly psychoactive. Its affinity to the CB2 receptor is higher than for the CB1 receptor.[24]

Source: http://en.wikipedia.org/wiki/Cannabinoids#Cannabinol

Tetrahydrocannabivarin aka THCv

Tetrahydrocannabivarin (THCVTHV) is a homologue of tetrahydrocannabinol (THC) having a propyl (3-carbon) side chain. This terpeno-phenolic compound is found naturally in Cannabis, sometimes in significant amounts. The psychoactive effects of THCV in Cannabis preparations are not well characterized.

Plants with elevated levels of propyl cannabinoids (including THCV) have been found in populations of Cannabis sativa L. ssp. indica (=Cannabis indica Lam.) from China, IndiaNepal, Thailand, Afghanistan, and Pakistan, as well as southern and western Africa. THCV levels up to 53.7% of total cannabinoids have been reported. [1] [2]

THCV has been shown to be a CB1 receptor antagonist, i.e. it blocks the effects of THC.[3]

Source: http://en.wikipedia.org/wiki/Tetrahydrocannabivarin

SATIVEX, GW Pharma’s Moneymaker?

Sativex, currently going through the later trials with the FDA, is about to set a precedent if their “drug” is approved for the U.S. Market. Why?

1) Their product is not synthetic. It’s a proprietary formulation made from natural cannabis plants, not synthetics like Marinol. Sativex, if approved, will be the first phytocannabinoid drug approved in the U.S. ever! This is groundbreaking.

2) Ok, so why is that important? Cannabis is currently Schedule 1, and regulated by the Federal Government like it has no medicinal uses. Even though Marinol is made from synthetic THC, and legal for prescription use, cannabis is illegal in the eyes of the government. “We don’t want you to be able to grow your medicine, buy synthetic!” Meanwhile, cocaine and opiates are Schedule 2, because they have medical uses. Does this make sense? Heck no.

So, if the FDA approves Sativex, it will be the third instance (that I can think of) of a Federal Agency disagreeing openly with the DEA and DOJ. The first instance being when a federal judge approved cannabis for medicinal consumption in 1976 (our Bicentennial, of all years). The University of Mississippi has been sending the remaining patients cannabis joints to this day. The second instance was the the Department of Health and Human Services patent for marijuana/cannabinoids. So, the government is banning cannabis but at the same time, gearing up to profit and/or protect it as intellectual property? I don’t understand their logic or intentions. Do you? As an American, it’s our right and duty to question our government, by the people – for the people.

Please allow me to share some of my research with you. I have cited my sources and urge you to explore on your own.

When Robert Randall took on the Federal Government:

“The origins of the Compassionate Investigational New Drug Study program began in 1976 after Robert Randall brought a lawsuit (Randall v. U.S) against the Food and Drug Administration, the Drug Enforcement Administration, the National Institute on Drug Abuse, the Department of Justice, and the Department of Health, Education & Welfare. Randall, afflicted with glaucoma, had successfully used the Common Law doctrine of necessity to argue against charges of marijuana cultivation because it was deemed a medical necessity (U.S. v. Randall). On November 24, 1976, federal Judge James Washington ruled:

“While blindness was shown by competent medical testimony to be the otherwise inevitable result of the defendant’s disease, no adverse effects from the smoking of marijuana have been demonstrated. Medical evidence suggests that the medical prohibition is not well-founded.”

The criminal charges against Randall were dropped, and following a petition (May 1976) filed by Randall, federal agencies began providing him with FDA-approved access to government supplies of medical marijuana, becoming the first American to receive marijuana for the treatment of a medical disorder. Randall went public with his victory and shortly after the government tried to prevent his legal access to marijuana. This led to the 1978 lawsuit where Randall was represented pro bono publico by law firm Steptoe & Johnson. Twenty-four hours after filing the suit, the federal agencies requested an out-of-court settlement which resulted in Randall gaining prescriptive access to marijuana through a federal pharmacy near his home.

The settlement in Randall v. U.S. became the legal basis for the FDA’s Compassionate IND program. Initially only available to patients afflicted by marijuana-responsive disorders and orphan drugs, the concept was expanded to include HIV-positive patients in the mid-1980s. Due to the growing number of AIDS patients throughout the late 1980s and the resulting numbers of patients who joined the Compassionate IND program, the George H. W. Bush administration closed the program down in 1992. At its peak, the program had thirty active patients.

Clinton A. Werner, author of “Medical Marijuana and the AIDS Crisis”, says that the closure of the government program during the height of the AIDS epidemic led directly to the formation of the medical cannabis movement in the United States, a movement which initially sought to provide cannabis for treating anorexia and wasting syndrome in AIDS patients.[2]

Source: http://en.wikipedia.org/wiki/Compassionate_Investigational_New_Drug_program

 

Federal Funding for Cannabis – And It’s Still Schedule 1?

Federal Funding, American tax dollars, for medical marijuana and marijuana research has been going on as early as 1968, yet it’s 2012 and a MD still can’t prescribe cannabis when paper after paper, and study after study, along with mountains of anecdotal evidence, prove beyond a reasonable doubt that cannabis can be used for healing a wide range of illnesses.

“Since 1968, the school operates the only legal marijuana farm and production facility in the United States. The National Institute on Drug Abuse (NIDA) contracts to the university the production of cannabis for the use in approved research studies on the plant as well as for distribution to the seven surviving medical cannabis patients grandfathered into the Compassionate Investigational New Drug program(established in 1978 and canceled in 1991).[38]

Source: http://en.wikipedia.org/wiki/University_of_Mississippi

If Sativex is approved in the United States for prescription use, it will be a landmark case. For the first time, a phytocannabinoid medicine will be covered by an insurance plan. Can you imagine! How many patients keep their cannabis treatment plan in the dark? How many American Citizens could benefit by re-education about the plant, it’s wonderful diversity and healing nature? It’s time we grow up when it comes to cannabis. It’s limitless if we allow ourselves to re-examine our culture of synthetic medicine and move back toward our roots in a natural lifestyle. The culture of convenience is killing us. If you treat the symptoms, but not the cause, you will continue to suffer. It’s that simple. Listen to your own intuition; follow your own path to the Light.

P.S. I hope that if Sativex is approved, Cannabis Science (OTC: CBIS) will have their application with the FDA expedited (or even better: approved in tandem), because why should a British company be able to get first to market when an American company is just as able. I’m not a Nationalist (I am horrified by history’s skeleton of the notion), but the economics of the situation, and the local supply, should be tilted in America’s favor. We have the capacity, know-how and passion to produce it. Homegrown, and the tax dollars will help the United States get out of debt. Everyone wins.

Disclaimer: I do own shares in Cannabis Science (OTC: CBIS). However, my intentions are pure. I want Cannabis completely legalized in the United States and I want American entrepreneurs to reap the rewards. Not big pharma, not the tobacco companies, not the alcohol companies… because they will just pervert it, grow it en masse with all kinds of chemicals and ruin the medicinal and nutritional benefits of the hemp plant with their cold, calculating economics. Monsanto reportedly has ties with GW Pharmaceuticals, although I haven’t been able to confirm that.